Ajooni Biotech share news, announcements and annual reports
NSE: AJOONIFood ProductsSmall Cap
Ajooni Biotech Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2018 · Issue price ₹40
Last close ₹2.94up ₹0.05 (1.73%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹2.89.
28 Oct: open ₹2.95, high ₹2.96, low ₹2.89
52-week range of traded prices to 28 Oct 2026
₹2.68Low, 12 Oct 2026₹5.50High, 9 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹53 Cr3,140th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.46
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 4.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,39,07562.6% delivered
Ajooni Biotech disputes and clarifications
44 filed, newest first.
Jul 2025
Jun 2025
25 Jun · Legal
Exchange has sought clarification from Ajooni Biotech Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Dec 2024
9 Dec · Legal
Exchange has sought clarification from Ajooni Biotech Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jun 2023
May 2023
26 May · Legal
Exchange has sought clarification from Ajooni Biotech Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Dec 2022
13 Dec · Legal
12 Dec · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to Financial Results dated 11-Nov-2022 for the period Sep, 2022On the basis of aforesaid disclosure, the Listed entity is required to clarify the following:Standalone: Cash Flow- Not submitted.The response of the company is awaited7 Dec · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 29-Nov-2022 informing about Communication to shareholders as per Reg 30.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief). 2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"; 3. Name of the target entity, details in brief such as size, turnover etc; 4. Industry to which the entity being acquired belongs; 5. Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); 6. Brief details of any governmental or regulatory approvals required for the acquisition; 7. Indicative time period for completion of the acquisition; 8. Cost of acquisition or the price at which the shares are acquired; 9. Nature of consideration - whether cash consideration or share swap and details of the same; The response of the company is awaited.
Sep 2022
Aug 2022
29 Aug · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 25-Aug-2022 informing about the Outcome of Board Meeting.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Rationale behind the split/consolidation; 2. Pre and post share capital - authorized, paid-up and subscribed; 3. Expected time of completion; 4. Class of shares which are consolidated or subdivided; 5. Number of shares of each class pre and post split or consolidation; 6. Amendments to Memorandum and/or Articles of association of listed entity, in brief. The response of the company is awaited.
Nov 2021
Sep 2021
Aug 2021
27 Aug · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 27-Aug-2021, regarding Amendments to Memorandum and/or Articles of association. On basis of above the Company is required to clarify following: 1. Amendments to Memorandum and/or Articles of association of listed entity, in brief.The response of the Company is awaited.
Jul 2021
12 Jul · Legal
Exchange has sought clarification from Ajooni Biotech Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Mar 2021
17 Mar · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 13-Mar-2021, regarding appointment of Secretarial Auditors for the F.Y. 2020-2021. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.
Nov 2020
20 Nov · Legal
Exchange has sought clarification from Ajooni Biotech Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Statement of Cash Flow not submitted The response of the Company is awaited.
Aug 2020
14 Aug · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 13-Aug-2020, regarding Appointment of Mr. Gursimran Singh as an Additional Director of the company. On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment2. Brief profile (in case of appointment)The response of the Company is awaited.
Jul 2020
3 Jul · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 29-Jun-2020, regarding board meeting held on Jun 29, 2020. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment) The response of the Company is awaited.
Feb 2020
13 Feb · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 12-Feb-2020, regarding Appointment of Company Secretary cum Compliance officer vide Board meeting held on February 12, 2020. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment). The response of the Company is awaited.
Nov 2019
13 Nov · Legal
Exchange has sought clarification from Ajooni Biotech Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Statement of Cash Flow not submitted The response of the Company is awaited.
Oct 2019
23 Oct · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 14-Oct-2019, that the Board of Directors in their meeting held on October 14, 2019 has considered and approved the resignation of Ms. Kanika Sapra, Company Secretary and Compliance Officer of the Company. On basis of above the Company is required to clarify following: 1. Date of resignation of Ms. Kanika Sapra. The response of the Company is awaited.
Jun 2019
3 Jun · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. No Segment Reporting. -2. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is awaited.
May 2019
3 May · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 25-Apr-2019, regarding Board meeting held on April 25, 2019.". On basis of above the Company is required to clarify following: 1. Whether intimated in 24hrs;2. Disclosure of relationships between directors (in case of appointment of a director);3. Brief profile (in case of appointment).The response of the Company is awaited.
Apr 2019
22 Apr · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 09-Apr-2019, regarding Board meeting held on April 09, 2019. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.
Mar 2019
1 Mar · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 15-Feb-2019, regarding Board meeting held on February 15, 2019.". On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointmentThe response of the Company is awaited.
Nov 2018
16 Nov · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted -2. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is awaited.
Jun 2018
6 Jun · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. No Segment Reporting. -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -3. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Apr 2018
3 Apr · Legal
Exchange has sought clarification from Ajooni Biotech Limited with respect to announcement dated 29-Mar-2018, regarding Outcome of Board Meeting held on January 01, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);2. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is awaited.